Can You Do Ketamine Therapy Alone? What to Know

Can You Do Ketamine Therapy Alone?

Technically, yes — but only in one model. Daily low-dose protocols are the only form of ketamine therapy where the medication itself is self-administered each day without anyone present during the act of taking it. A prescribing clinician is still involved in the initial evaluation and ongoing prescription, but no session-level supervision takes place.

The published evidence base for this specific protocol is limited. The only trial to ever test true once-daily oral racemic ketamine for depression was a 28-day open-label study in 14 hospice patients (Irwin 2013).¹ No published trial has tested this protocol in the general outpatient population that commercial daily-dosing providers serve.

Every other form of ketamine therapy is administered with someone present — a clinician on-site at a clinic, or a peer treatment monitor physically present during at-home sessions. The next section walks through how supervision differs across the full spectrum.

What "Doing Ketamine Therapy Alone" Actually Means: The Supervision Spectrum

The concept of doing ketamine therapy "alone" sits on a spectrum with four distinct levels of supervision. Understanding these levels helps clarify what safeguards are in place for each approach.

• In-clinic, clinician-administered: A licensed clinician administers ketamine via intravenous infusion or intramuscular injection in a medical facility. They monitor the patient on-site throughout the entire session.
• Clinician-prescribed at-home with defined oversight: A licensed clinician prescribes ketamine after a thorough health screening. Sessions take place at home following a specified protocol, with a peer treatment monitor physically present during every session. The provider manages ongoing dosage, and integration support is part of the program.
• Daily low-dose self-administration: Some providers prescribe low daily oral doses of ketamine intended to be taken like a daily medication. Patients self-administer each day without session-level supervision or a peer treatment monitor.
• Fully unsupervised or illicit use: Obtaining ketamine without a prescribing clinician, without screening, and without dosing guidance carries the highest risk. It offers no supervised safeguards.

The published evidence supporting ketamine therapy is concentrated in supervised, protocol-driven care. The rest of this article focuses on what that looks like in practice.

The Roles That Make Ketamine Therapy Supervised: Prescribing Clinician, Session Monitor, Integration Support

Supervision in ketamine therapy is a system of three distinct functions that operate before, during, and after each session.

• Prescribing clinician: A licensed clinician conducts initial medical screening, determines eligibility, and sets the dosing protocol. They provide ongoing oversight, including consults and dosage adjustments, acting as the primary gatekeeper for safety.
• In-session monitor (during the session): Who fills this role depends on the treatment setting. In-clinic ketamine therapy is administered by a clinician on-site, who typically monitors the patient throughout the session. Because at-home ketamine therapy takes place outside a clinical setting, many at-home providers require a support person to be physically present instead. At Mindbloom, a peer treatment monitor is required for every session, and clients arrange their own peer treatment monitor before treatment begins.
• Integration support (between sessions): Structured reflection practices help clients process and apply insights from each session. This typically includes guide coaching, group integration circles, and journaling, and is what helps connect the neuroplastic window opened by ketamine to durable cognitive and behavioral change. Integration is a core component of most clinician-prescribed at-home programs; many in-clinic providers focus on medication administration and do not include structured integration support.

The three roles together — prescribing, monitoring, integration — are what produce the safety and outcomes profile reported in the published evidence base for supervised ketamine therapy.

Is Ketamine Therapy Safe Without Clinical Supervision?

Safety in ketamine therapy is a function of screening, clinical oversight, and structured protocols — not setting or dose size on their own. Within protocol-driven programs, ketamine's known physiological effects (temporary increases in blood pressure, occasional nausea or dizziness) and psychological effects (dissociation, transient anxiety) are anticipated, screened for, and managed in-session. Pre-session cardiovascular evaluation, dosing oversight by the prescribing clinician, and the required peer treatment monitor are what create the safety profile reflected in the published evidence. In a study of 11,441 participants using the Mindbloom protocol, side effects occurred in approximately 4 to 5% of sessions, and serious adverse events occurred in fewer than 0.1%.²

Do You Need a Therapist, a Support Person, or Both?

A licensed therapist, a peer treatment monitor, and integration coaching serve different functions in ketamine therapy.

A licensed therapist is not required for ketamine therapy, but many people find that therapy alongside ketamine deepens the work. Ketamine-assisted psychotherapy is a specific modality where a therapist is present during or immediately after the session. At-home programs use a different model where the peer treatment monitor is present for safety, and integration coaching provides support between sessions.

• Peer treatment monitor: Required to be present during the session for physical safety and grounding.
• Integration coaching and circles: Provided between sessions to help translate session insights into lasting change.
• Licensed therapist: Optional but potentially valuable for ongoing care. Some clients work with their own therapist in parallel, while others find integration support sufficient.

A comprehensive program ensures the clinical and integration roles are covered regardless of whether you also see a therapist.

At-Home vs In-Clinic Ketamine Therapy: Which Fits Best?

Choosing between at-home and in-clinic care is a decision between two legitimate clinical approaches. Each is suited to different needs and preferences, and neither is inherently superior.

In-clinic IV/IM ketamine, provider-supervised at-home ketamine, and Spravato differ in administration, setting, supervision, FDA status, and cost. The table below outlines the key differences between these options.

In-Clinic Ketamine Therapy Best Fit

In-clinic care suits individuals with complex medical histories who benefit from direct on-site monitoring throughout each session, those who prefer the structure of a clinical setting, or those whose clinician determines that intravenous or intramuscular administration is appropriate for their care plan.

Intravenous ketamine is an established modality with a strong evidence base.

At-Home Ketamine Therapy Best Fit

At-home ketamine therapy may suit individuals who value the comfort and familiarity of their own environment. Those seeking a defined program with integration support beyond the dosing session often prefer this model.

The at-home model is also helpful for those for whom cost or geographic access to a clinic is a barrier. Mindbloom's at-home ketamine therapy starts at $165 per guided session for an 18-session program, billed in monthly installments of $330 for 9 months. A 6-session program starts at $215 per session, billed as $430 per month for 3 months. Returning clients pay as little as $129 per session with an 18-session program.

Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy (Hull 2022, n=1,247; Mathai 2024, n=11,441), with 89% of Hull 2022 participants reporting symptom improvement for anxiety and depression.^3,2 Mindbloom offers both sublingual tablets and subcutaneous injectables, enabling more consistent dosing for clients whose clinicians determine subcutaneous administration fits their care plan.

The right choice depends on medical needs, personal preferences, and practical considerations. Treatment setting does not inherently determine effectiveness when protocols are supervised.

Who Qualifies for At-Home Ketamine Therapy?

Eligibility for at-home ketamine therapy is determined through a comprehensive evaluation by a licensed clinician rather than through self-selection.

Mindbloom offers programs of 6, 12, or 18 sessions. After you select a program, a licensed clinician conducts a comprehensive medical evaluation to confirm your eligibility and personalize your care plan. Screening typically evaluates several key areas.

• Mental health history and current symptoms: Ketamine therapy may be appropriate for adults experiencing depression, anxiety, PTSD, or related conditions. Prior treatment failure is not a prerequisite.
• Medical history: The clinician will review cardiovascular health, liver and kidney function, and other conditions that may affect eligibility.
• Contraindications: Ketamine therapy may not be appropriate for individuals with psychotic disorders, active substance use disorders, uncontrolled hypertension, serious cardiac or respiratory conditions, or pregnancy.
• Medication review: Certain medications may interact with ketamine. The prescribing clinician reviews current prescriptions to ensure safety.

Only a licensed clinician can determine eligibility; it is not a checklist you can complete on your own. Doing ketamine therapy without a prescribing clinician is fundamentally different from at-home care with supervised oversight.

How Mindbloom's Care Protocols Manage Supervision Across Every Session

Mindbloom's care model is built around the principle that ketamine therapy requires more than medication. It requires a structured program that includes clinical oversight, in-session safety, and post-session integration.

• Clinical evaluation and eligibility screening: A licensed clinician conducts a comprehensive medical and psychiatric evaluation before treatment begins to confirm eligibility and personalize the care plan.
• Clinician-determined dosing: Dosing is sub-anesthetic and personalized by the prescribing clinician. Treatment frequency is set by the clinician based on individual needs.
• Peer treatment monitor requirement: A trained peer treatment monitor must be physically present during every session; clients arrange their own peer treatment monitor before treatment begins.
• Session protocol: Each session follows a set format including preparation, the dosing session itself, and a post-session transition period. Clients should avoid driving until after a full night of sleep.
• Integration support: Each program includes guide coaching sessions, unlimited guide messaging, and unlimited Group Integration Circles. Integration support, described earlier, helps sustain the cognitive and behavioral gains from each session.
• Ongoing clinical oversight: Clinician consults are built into every program for dosage management and progress evaluation.
• Administration options: Mindbloom is the only at-home ketamine provider offering subcutaneous administration in addition to sublingual tablets. Subcutaneous options enable more consistent dosing for clients who prefer it.

Mindbloom has published two of the largest peer-reviewed, real-world outcomes studies of at-home ketamine therapy (Hull 2022, n=1,247; Mathai 2024, n=11,441).^3,2 In Hull et al. 2022, 89% of Mindbloom participants reported symptom improvement for anxiety and depression. In Mathai et al. 2024, side effects occurred in approximately 4 to 5% of sessions and serious adverse events occurred in fewer than 0.1%. Individual results may vary; outcomes were measured using validated instruments (PHQ-9 and GAD-7).

Conclusion

'Alone' in ketamine therapy means different things across the supervision spectrum, and only one model — daily low-dose self-administration — actually involves taking the medication without anyone present. Every other format includes session-level supervision by design, whether that's a clinician on-site at a clinic or a peer treatment monitor at home. A licensed clinician can help determine which format fits your clinical needs.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.